WO2024099400A1 - Intermédiaires et procédé de composés pour la dégradation de la kinase egfr - Google Patents

Intermédiaires et procédé de composés pour la dégradation de la kinase egfr Download PDF

Info

Publication number
WO2024099400A1
WO2024099400A1 PCT/CN2023/130819 CN2023130819W WO2024099400A1 WO 2024099400 A1 WO2024099400 A1 WO 2024099400A1 CN 2023130819 W CN2023130819 W CN 2023130819W WO 2024099400 A1 WO2024099400 A1 WO 2024099400A1
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
hydrogen
butyl
alkynyl
alkenyl
Prior art date
Application number
PCT/CN2023/130819
Other languages
English (en)
Inventor
Bailin LEI
Huaqing Liu
Yizhou ZHAO
Songzhe HAN
Shaohan LIAO
Jia Tang
Zhiwei Wang
Original Assignee
Beigene (Beijing) Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beigene (Beijing) Co., Ltd. filed Critical Beigene (Beijing) Co., Ltd.
Publication of WO2024099400A1 publication Critical patent/WO2024099400A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Definitions

  • novel bifunctional compounds formed by conjugating EGFR inhibitor moieties with E3 ligase Ligand moieties, which function to recruit targeted proteins to E3 ubiquitin ligase for degradation, and methods of preparation and uses thereof.
  • Proteolysis targeting chimera consists of two covalently linked protein-binding molecules: one capable of engaging an E3 ubiquitin ligase, and another that binds to the protein of interest (POI) a target meant for degradation (Sakamoto KM et al., Proc. Natl. Acad. Sci. 2001, 98: 8554–9. ; Sakamoto K. M. et al., Methods Enzymol. 2005; 399: 833 ⁇ 847. ) . Rather than inhibiting the target protein's enzymatic activity, recruitment of the E3 ligase to the specific unwanted proteins results in ubiquitination and subsequent degradation of the target protein by the proteasome.
  • ubiquitin–proteasome pathway The whole process of ubiquitination and proteasomal degradation is known as the ubiquitin–proteasome pathway (UPP) (Ardley H. et al., Essays Biochem. 2005, 41, 15-30; Komander D. et al., Biochem. 2012, 81, 203-229; Grice G. L. et al., Cell Rep. 2015, 12, 545-553; Swatek K. N. et al., Cell Res. 2016, 26, 399-422) .
  • Proteasomes are protein complexes which degrade unneeded, misfolded or abnormal proteins into small peptides to maintain health and productivity of the cells.
  • Ubiquitin ligases also called an E3 ubiquitin ligase, directly catalyze the transfer of ubiquitin from the E2 to the target protein for degradation.
  • E3 ubiquitin ligases also called an E3 ubiquitin ligase, directly catalyze the transfer of ubiquitin from the E2 to the target protein for degradation.
  • the human genome encodes over 600 putative E3 ligases, only a limited number of E3 ubiquitin ligases have been widely applied by small molecule PROTAC technology: cereblon (CRBN) , Von Hippel-Lindau (VHL) , mouse double minute 2 homologue (MDM2) and cellular inhibitor of apoptosis protein (cIAP) (Philipp O. et al., Chem. Biol. 2017, 12, 2570-2578) , recombinant Human Ring Finger Protein 114 (RNF114) (Spradlin, J.
  • Immunomodulatory drugs including thalidomide, lenalidomide, and pomalidomide, function as monovalent promoters of PPIs by binding to the cereblon (CRBN) subunit of the CRL4A CRBN E3 ligase complex and recruiting neosubstrate proteins.
  • CRBN cereblon
  • PROTACs proteolysis-targeting chimeras
  • PROTACs have great potential to eliminate protein targets that are “undruggable” by traditional inhibitors or are non-enzymatic proteins.
  • PROTACs as useful modulators promote the selective degradation of a wide range of target proteins have been reported in antitumor studies.
  • Epidermal growth factor receptor that belongs to the ErbB family is a transmembrane receptor tyrosine kinase (RTK) , which plays a fundamentally key role in cell proliferation, differentiation, and motility (Y. Yarden, et al., Nat. Rev. Mol. Cell Biol. 2001; 2: 127-137. ) .
  • RTK transmembrane receptor tyrosine kinase
  • Homo-or heterodimerization of EGFR and other ErbB family members activates cytoplasmic tyrosine kinase domains to initiate intracellular signaling.
  • Overexpression or activating mutations of EGFR are associated the development of many types of cancers, such as pancreatic cancer, breast cancer, glioblastoma multiforme, head and neck cancer, and non-small cell lung cancer (Yewale C., et al. Biomaterials. 2013, 34 (34) : 8690-8707. ) .
  • the activating mutations in the EGFR tyrosine kinase domain (L858R mutation and exon-19 deletion) have been identified as oncogenic drivers for NSCLC (Konduri, K., et al. Cancer Discovery 2016, 6 (6) , 601-611. ) .
  • the first-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs) gefitinib and erlotinib have approved for NSCLC patients with EGFR activation mutations (M. Maemondo, N. Engl. J. Med. 362 (2010) 2380-2388. ) . Although most patients with EGFR mutant NSCLC respond to these therapies, patients typically develop resistance after an average of one year on treatment. There are several mechanisms of acquired resistance to gefitinib and erlotinib, including a secondary threonine 790 to methionine 790 mutation (T790M) , is also called “gatekeeper” T790M mutation (Xu Y., et al. Cancer Biol Ther.
  • T790M secondary threonine 790 to methionine 790 mutation
  • the second-generation EGFR-TKIs afatinib and the third-generation EGFR-TKIs osimertinib were developed as irreversible EGFR inhibitors that bind to Cys797 for the treatment of patients with T790M mutation.
  • osimertinib that largely spares WT EGFR has achieved greater clinical response rate in NSCLC patients with EGFR T790M.
  • C797S tertiary Cys797 to Ser797
  • EGFR-Targeting PROTACs serve as a potential strategy to overcome drug resistance mediated by these mutants, which has been disclosed or discussed in patent publications, e.g. WO2018119441, WO2019149922, WO2019183523, WO2019121562, US20190106417, WO202157882, WO2021123087, WO2021133809, WO2021168074, WO2021208918 and WO2021216440.
  • the present application provides the intermediates and process of novel bifunctional compounds for the treatment of serious diseases.
  • One objective of the present invention is to provide compounds and derivatives formed by conjugating EGFR inhibitor moieties with E3 ligase Ligand moieties, which function to recruit targeted proteins to E3 ubiquitin ligase for degradation, and methods of preparation and uses thereof.
  • PCT/CN2022/131085 and PCT/CN2023/097329 disclosed a series of bifunctional compounds formed by conjugating EGFR inhibitor moieties with E3 ligase Ligand moieties.
  • the compounds disclosed by PCT/CN2022/131085 and PCT/CN2023/097329 described herein or salts thereof are useful in the treatment of a disease that can be affected by EGFR modulation.
  • the present invention provides the use of the compounds described herein or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a disease that can be affected by EGFR modulation.
  • the present invention further provides a compound described herein or a pharmaceutically acceptable salt thereof, for use in the treatment of a disease that can be affected by EGFR modulation.
  • the present application further provides a method of treating a proliferative disorder, comprising administering to a subject in need thereof a therapeutically effective amount of the compounds described herein or a pharmaceutically acceptable salt thereof.
  • E 1 is N or CR 5 ;
  • E 2 is N or CR 6 ;
  • R 1a , R 1b , R 2a and R 2b are each independently absence, hydrogen, halogen, -C 1-8 alkyl, -C 2- 8 alkenyl, -C 2-8 alkynyl, -C 1-8 alkoxy, -C 3-8 cycloalkyl or -CN; each said -C 1-8 alkyl, -C 2-8 alkenyl, -C 2-8 alkynyl, -C 1-8 alkoxy, or -C 3-8 cycloalkyl is optionally substituted with at least one substituent selected from hydrogen, halogen, -C 1-8 alkoxy, -C 3-8 cycloalkyl or -CN;
  • R 3 and R 4 are each independently hydrogen, -C 1-6 alkyl, or -C 3-8 cycloalkyl; each said -C 1- 6 alkyl or -C 3-8 cycloalkyl is optionally substituted with at least one substituent selected from hydrogen, halogen, -C 1-6 alkoxy;
  • R 5 and R 6 are each independently absence, hydrogen, halogen, -C 1-8 alkyl, -C 2-8 alkenyl, -C 2-8 alkynyl, -C 1-8 alkoxy, -C 3-8 cycloalkyl or -CN; each said -C 1-8 alkyl, -C 2-8 alkenyl, -C 2- 8 alkynyl, -C 1-8 alkoxy, or -C 3-8 cycloalkyl is optionally substituted with at least one substituent selected from hydrogen, halogen, -C 1-8 alkoxy, -C 3-8 cycloalkyl or -CN; or
  • R 5 and R 6 with the carbon atoms to which they are attached, form a 3-to 12-membered ring, said ring comprising 0-3 heteroatoms independently selected from nitrogen, oxygen or sulfur; said ring is optionally substituted with at least one substituent halogen, hydroxy, or -C 1 -C 8 alkyl;
  • R 7 is each independently absence, hydrogen, halogen, -C 1-8 alkyl, -C 2-8 alkenyl, -C 2- 8 alkynyl, -C 1-8 alkoxy, -C 3-8 cycloalkyl or -CN; each said -C 1-8 alkyl, -C 2-8 alkenyl, -C 2-8 alkynyl, -C 1-8 alkoxy, or -C 3-8 cycloalkyl is optionally substituted with at least one substituent selected from hydrogen, halogen, -C 1-8 alkoxy, -C 3-8 cycloalkyl or -CN; or
  • R 7 with the carbon atom (s) to which they are attached, form a 3-to 12-membered ring, said ring comprising 0-3 heteroatoms independently selected from nitrogen, oxygen or sulfur; said ring is optionally substituted with at least one substituent halogen, hydroxy, or -C 1 -C 8 alkyl;
  • R 8 and R 9 are each independently selected from hydrogen, halogen, -C 1 -C 6 alkyl or C 3 -C 8 cycloalkyl; each of -C 1 -C 6 alkyl or C 3 -C 8 cycloalkyl is optionally substituted with at least one substituent selected from hydrogen, halogen, -C 1-6 alkoxy;
  • R 10 is each independently selected from hydrogen, halogen, -C 1 -C 8 alkyl, -C 2-8 alkenyl, -C 2-8 alkynyl, C 3 -C 8 cycloalkyl, 3-to 8-membered heterocyclyl, C 6 -C 12 aryl, 5-to 12-membered heteroaryl, -NR 10a R 10b , -OR 10a , -SR 10a , -C (O) R 10a , -CO 2 R 10a , -C (O) NR 10a R 10b , -NR 10a COR 10b , -NR 10a CO 2 R 10b or -NR 10a SO 2 R 10b or -CN; each of -C 1 -C 8 alkyl, -C 2-8 alkenyl, -C 2-8 alkynyl, C 3 -C 8 cycloalkyl, 3-to 8-membered heterocyclyl, C 6 -C 12
  • R 10a and R 10b are each independently selected from hydrogen, -C 1 -C 8 alkyl, -C 2 -C 8 alkenyl, -C 2 -C 8 alkynyl, C 3 -C 8 cycloalkyl, 3-to 8-membered heterocyclyl, C 6 -C 12 aryl, or 5-to 12-membered heteroaryl, each of said -C 1 -C 8 alkyl, -C 2 -C 8 alkenyl, -C 2 -C 8 alkynyl, C 3 -C 8 cycloalkyl, 3-to 8-membered heterocyclyl, C 6 -C 12 aryl, or 5-to 12-membered heteroaryl is optionally substituted with at least one substituent R 10d ;
  • R 10e and R 10f are each independently selected from hydrogen, -C 1 -C 8 alkyl, -C 2 -C 8 alkenyl, -C 2 -C 8 alkynyl, C 3 -C 8 cycloalkyl, 3-to 8-membered heterocyclyl, C 6 -C 12 aryl, or 5-to 12-membered heteroaryl;
  • R 11a , R 11b , R 11c , R 11d , R 12a , R 12b , R 12c and R 12d are each independently absence, oxo, hydrogen, halogen, -C 1-8 alkyl, -C 2-8 alkenyl, -C 2-8 alkynyl, -C 1-8 alkoxy or -C 3-8 cycloalkyl; each of said -C 1-8 alkyl, -C 2-8 alkenyl, -C 2-8 alkynyl, -C 1-8 alkoxy or -C 3-8 cycloalkyl is optionally substituted with at least one substituent selected from hydrogen, halogen, -C 1-8 alkyl, -C 2- 8 alkenyl, -C 2-8 alkynyl, -C 1-8 alkoxy or -CN;
  • L 1 is independently selected from -O-, -NR a -, -C (O) -, * L1 -C (O) NR a -** L1 , * L1 -C (O) O-** L1 , * L1 -NR a C (O) -** L1 , * L1 -OC (O) -** L1 , wherein each of said is optionally substituted with at least one R L1c ;
  • L 2 is independently selected from -O-, -NR a -, -C (O) -, * L2 -C (O) NR a -** L2 , * L2 -C (O) O-** L2 , * L2 -NR a C (O) -** L2 , * L2 -OC (O) -** L2 , wherein each of said is optionally substituted with at least one R L2c ;
  • L 3 is independently selected from -O-, -NR a -, -C (O) -, * L3 -C (O) NR a -** L3 , * L3 -C (O) O-** L3 , * L3 -NR a C (O) -** L3 , * L3 -OC (O) -** L3 , wherein each of said is optionally substituted with at least one R L3c ;
  • * L3 refers to the position attached to the moiety, and ** L3 refers to the position attached to the moiety;
  • Z 1 and Z 2 are each independently N or CR z ;
  • R z at each occurrence, is independently selected from absence, hydrogen, halogen, -C 1- 8 alkyl, -NR Za R Zb , -OR Za , -SR Za , C 3 -C 8 cycloalkyl, 3-to 8-membered heterocyclyl or CN; each of -C 1-8 alkyl, C 3 -C 8 cycloalkyl, 3-to 8-membered heterocyclyl is optionally substituted with at least one R Zc ;
  • R Za and R Zb are each independently selected from absence, hydrogen, -C 1 -C 8 alkyl, C 3 -C 8 cycloalkyl, 3-to 8-membered heterocyclyl, C 6 -C 12 aryl, or 5-to 12-membered heteroaryl, each of said -C 1-8 alkyl, C 3 -C 8 cycloalkyl, 3-to 8-membered heterocyclyl, C 6 -C 12 aryl, or 5-to 12-membered heteroaryl is optionally substituted with at least one substituent R Zd ;
  • R Zc and R Zd are each independently halogen, hydroxy, -C 1 -C 8 alkyl, -C 1-8 alkoxy, C 3 -C 8 cycloalkyl, 3-to 8-membered heterocyclyl, C 6 -C 12 aryl, or 5-to 12-membered heteroaryl;
  • R 13 is each independently selected from absence, hydrogen, halogen, -C 1-8 alkyl, -C 2- 8 alkenyl, -C 2-8 alkynyl, -C 1-8 alkoxy, -C 3 -C 8 cycloalkyl, 3-to 8-membered heterocyclyl, -C 6 -C 12 aryl, 5-to 12-membered heteroaryl, -CN, -SO 2 R 13a , -SO 2 NR 13a R 13b , -COR 13a , -CO 2 R 13a , -CONR 13a R 13b , -NR 13a R 13b , -NR 13a COR 13b , -NR 13a CO 2 R 13b , or –NR 13a SO 2 R 13b ; each of -C 1- 8 alkyl, -C 2-8 alkenyl, -C 2-8 alkynyl, -C 1-8 alkoxy, -C 3 -C 8 cycl
  • R 13a , R 13b , R 13c and R 13d are each independently absence, hydrogen, -C 1-8 alkyl, -C 2-8 alkenyl, -C 2-8 alkynyl, C 3 -C 8 cycloalkyl, 3-to 8-membered heterocyclyl, C 6 -C 12 aryl, or 5-to 12-membered heteroaryl;
  • X 1 , X 2 and X 7 are each independently selected from -CR a , or N;
  • X 3 , X 4 and X 8 are each independently selected from -NR a -, -O-, -S-and -CR a R b -;
  • X 5 and X 6 are each independently selected from absence, single bond, -C (O) -, -NR a -and -O-;
  • R a and R b are each independently selected from hydrogen, hydroxy, halogen, CN, -C 1 -C 8 alkyl, -C 1 -C 8 alkoxy, -C 2 -C 8 alkenyl, -C 2 -C 8 alkynyl, -C 3 -C 8 cycloalkyl, 3-to 8-membered heterocyclyl, -C 6 -C 12 aryl or 5-to 12-membered heteroaryl, each of said -C 1 - C 8 alkyl, -C 1 -C 8 alkoxy, -C 2 -C 8 alkenyl, -C 2 -C 8 alkynyl, -C 3 -C 8 cycloalkyl, 3-to 8-membered heterocyclyl, -C 6 -C 12 aryl or 5-to 12-membered heteroaryl is optionally substituted with at least one substituent halogen, hydroxy, halogen, -
  • R a and R b together with the carbon atoms to which they are attached, form a 3-to 12-membered ring, said ring comprising 0-3 heteroatoms independently selected from nitrogen, oxygen or sulfur; said ring is optionally substituted with at least one substituent halogen, hydroxy, -C 1 -C 8 alkyl, -C 2 -C 8 alkenyl, -C 2 -C 8 alkynyl, -C 1 -C 8 alkoxy, -C 2 -C 8 alkenyl, -C 2 -C 8 alkynyl, C 3 -C 8 cycloalkyl, 3-to 8-membered heterocyclyl, C 6 -C 12 aryl or 5-to 12-membered heteroaryl;
  • n1, m2, m3 and m4 are each independently 0, 1 or 2; provided that m1+m2+m3+m4 ⁇ 4;
  • n1, n2, n3, n4 and n5 are each independently 0, 1, 2 or 3;
  • n6 is each independently 0, 1, 2, 3 or 4;
  • s1 and s2 are each independently 0, 1, 2 or 3;
  • s3 and s4 are each independently 1, 2 or 3;
  • s5, s6 and s7 are each independently 0, 1, 2 or 3;
  • One another objective of the present invention is to provide intermediates and process of compound (X) which formed by conjugating EGFR inhibitor moieties with E3 ligase Ligand moieties, which function to recruit targeted proteins to E3 ubiquitin ligase for degradation, and methods of preparation and uses thereof.
  • R 1a , R 1b , R 2a and R 2b are each independently absence, hydrogen, halogen, -C 1-8 alkyl, -C 2- 8 alkenyl, -C 2-8 alkynyl, -C 1-8 alkoxy, -C 3-8 cycloalkyl or -CN; each said -C 1-8 alkyl, -C 2-8 alkenyl, -C 2-8 alkynyl, -C 1-8 alkoxy, or -C 3-8 cycloalkyl is optionally substituted with at least one substituent selected from hydrogen, halogen, -C 1-8 alkoxy, -C 3-8 cycloalkyl or -CN;
  • R 3 and R 4 are each independently absence, hydrogen, -C 1-8 alkyl, -C 2-8 alkenyl, -C 2- 8 alkynyl or -C 3-8 cycloalkyl; each said -C 1-8 alkyl, -C 2-8 alkenyl, -C 2-8 alkynyl or -C 3-8 cycloalkyl is optionally substituted with at least one substituent selected from hydrogen, halogen, -C 1- 8 alkoxy, -C 3-8 cycloalkyl or -CN;
  • R 5 and R 6 are each independently absence, hydrogen, halogen, -C 1-8 alkyl, -C 2-8 alkenyl, -C 2-8 alkynyl, -C 1-8 alkoxy, -C 3-8 cycloalkyl or -CN; each said -C 1-8 alkyl, -C 2-8 alkenyl, -C 2- 8 alkynyl, -C 1-8 alkoxy, or -C 3-8 cycloalkyl is optionally substituted with at least one substituent selected from hydrogen, halogen, -C 1-8 alkoxy, -C 3-8 cycloalkyl or -CN; or
  • R 5 and R 6 with the carbon atoms to which they are attached, form a 3-to 12-membered ring, said ring comprising 0-3 heteroatoms independently selected from nitrogen, oxygen or sulfur; said ring is optionally substituted with at least one substituent halogen, hydroxy, or -C 1 -C 8 alkyl;
  • R 7 is each independently absence, hydrogen, halogen, -C 1-8 alkyl, -C 2-8 alkenyl, -C 2- 8 alkynyl, -C 1-8 alkoxy, -C 3-8 cycloalkyl or -CN; each said -C 1-8 alkyl, -C 2-8 alkenyl, -C 2-8 alkynyl, -C 1-8 alkoxy, or -C 3-8 cycloalkyl is optionally substituted with at least one substituent selected from hydrogen, halogen, -C 1-8 alkoxy, -C 3-8 cycloalkyl or -CN; or
  • R 7 with the carbon atom (s) to which they are attached, form a 3-to 12-membered ring, said ring comprising 0-3 heteroatoms independently selected from nitrogen, oxygen or sulfur; said ring is optionally substituted with at least one substituent halogen, hydroxy, or -C 1 -C 8 alkyl;
  • R 8 , R 9 and R 10 are each independently selected from hydrogen, halogen, -C 1 -C 8 alkyl, -C 2- 8 alkenyl, -C 2-8 alkynyl, C 3 -C 8 cycloalkyl, 3-to 8-membered heterocyclyl, C 6 -C 12 aryl, 5-to 12-membered heteroaryl, -NR 8a R 8b , -OR 8a , -SR 8a , -C (O) R 8a , -CO 2 R 8a , -C (O) NR 8a R 8b , -NR 8a COR 8b , -NR 8a CO 2 R 8b or -NR 8a SO 2 R 8b or -CN; each of -C 1 -C 8 alkyl, -C 2-8 alkenyl, -C 2- 8 alkynyl, C 3 -C 8 cycloalkyl, 3-to 8-membered heterocyclyl,
  • R 8a and R 8b are each independently selected from hydrogen, -C 1 -C 8 alkyl, -C 2 -C 8 alkenyl, -C 2 -C 8 alkynyl, C 3 -C 8 cycloalkyl, 3-to 8-membered heterocyclyl, C 6 -C 12 aryl, or 5-to 12-membered heteroaryl, each of said -C 1 -C 8 alkyl, -C 2 -C 8 alkenyl, -C 2 -C 8 alkynyl, C 3 -C 8 cycloalkyl, 3-to 8-membered heterocyclyl, C 6 -C 12 aryl, or 5-to 12-membered heteroaryl is optionally substituted with at least one substituent R 8d ;
  • R 8e and R 8f are each independently selected from hydrogen, -C 1 -C 8 alkyl, -C 2 -C 8 alkenyl, -C 2 -C 8 alkynyl, C 3 -C 8 cycloalkyl, 3-to 8-membered heterocyclyl, C 6 -C 12 aryl, or 5-to 12-membered heteroaryl;
  • R 11 is selected from halogen, -C 1 -C 8 alkyl, C 3 -C 8 cycloalkyl, 3-to 8-membered heterocyclyl, C 6 -C 12 aryl, or 5-to 12-membered heteroaryl, each of -C 1 -C 8 alkyl, C 3 -C 8 cycloalkyl, 3-to 8-membered heterocyclyl, C 6 -C 12 aryl, or 5-to 12-membered heteroaryl is optionally substituted with at least one R 11a ;
  • R 11b and R 11c are each independently selected from hydrogen, -C 1 -C 8 alkyl, -C 2 -C 8 alkenyl, -C 2 -C 8 alkynyl, C 3 -C 8 cycloalkyl, 3-to 8-membered heterocyclyl, C 6 -C 12 aryl, or 5-to 12-membered heteroaryl, each of said -C 1 -C 8 alkyl, -C 2 -C 8 alkenyl, -C 2 -C 8 alkynyl, C 3 -C 8 cycloalkyl, 3-to 8-membered heterocyclyl, C 6 -C 12 aryl, or 5-to 12-membered heteroaryl is optionally substituted with at least one substituent R 11f ;
  • R 11g and R 11h are each independently selected from hydrogen, -C 1 -C 8 alkyl, -C 2 -C 8 alkenyl, -C 2 -C 8 alkynyl, C 3 -C 8 cycloalkyl, 3-to 8-membered heterocyclyl, C 6 -C 12 aryl, or 5-to 12-membered heteroaryl.
  • Aspect 2 The synthetic method of Aspect 1, wherein the compound is selected from formula (Ia) ,
  • the compound is selected from formula (Ib) or (Ic)
  • the compound is selected from formula (Id) or (Ie)
  • R 1a , R 1b , R 2a , R 2b , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 are as defined in any one of the preceding Aspects.
  • Aspect 3 The synthetic method of any one of the preceding Aspects, wherein R 3 and R 4 are each independently hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 alkenyl, -C 2-8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl; said methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 alkenyl, -C 2- 8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl is optionally substituted with at least one
  • R 3 and R 4 are each independently hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl;
  • R 3 is independently methyl or cyclopropyl, and R 4 is hydrogen.
  • R 1a , R 1b , R 2a and R 2b are each independently hydrogen, F, Cl, Br, I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 alkenyl, -C 2-8 alkynyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl or -CN; wherein each said methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 alkenyl,
  • R 1a , R 1b , R 2a and R 2b are each independently hydrogen, F, Cl, Br, I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, -CF 3 , -CHF 2 , -CN, -CH 2 OCH 3 , -CH 2 OCH 2 CH 3 , -CH 2 CH 2 OCH 3 , -CH 2 CH 2 OCH 2 CH 3 ;
  • R 1a , R 1b , R 2a and R 2b are each independently hydrogen, F, Cl, methyl, methoxy, cyclopropyl, -CF 3 or -CHF 2 , -CH 2 OCH 3 ;
  • R 1a , R 1b , R 2a and R 2b are each independently hydrogen.
  • R 5 and R 6 are each independently hydrogen, F, Cl, Br, I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, -CF 3 , -CHF 2 , -CN, -CH 2 OCH 3 , -CH 2 OCH 2 CH 3 , -CH 2 CH 2 OCH 3 , -CH 2 CH 2 OCH 2 CH 3 ;
  • R 5 and R 6 are each independently hydrogen, F, Cl, methyl, methoxy, cyclopropyl, -CF 3 or -CHF 2 , -CH 2 OCH 3 .
  • Aspect 6 The synthetic method of any one of the preceding Aspects, wherein R 5 and R 6 with the carbon atoms to which they are attached, form a 3-, 4-, 5-, 6-, 7-or 8-membered ring, said ring comprising 0-3 heteroatoms independently selected from nitrogen, oxygen or sulfur; said ring is optionally substituted with at least one substituent F, Cl, Br, I, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl or octyl;
  • Aspect 7 The synthetic method of any one of the preceding Aspects, wherein R 7 are each independently hydrogen, F, Cl, Br, I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptyloxy, octyloxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, -CF 3 , -CHF 2 , -CN, -CH 2 OCH 3 , -CH 2 OCH 2 CH 3 , -CH 2 CH 2 OCH 3 , -CH 2 CH 2 OCH 2 CH 3 ;
  • R 7 are each independently hydrogen, F, Cl, methyl, methoxy, cyclopropyl, -CF 3 or -CHF 2 , -CH 2 OCH 3 .
  • Aspect 8 The synthetic method of any one of the preceding Aspects, wherein R 8 , R 9 and R 10 are each independently selected from hydrogen, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 alkenyl, -C 2-8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3-to 8-membered heterocyclyl, phenyl, 5-to 12-membered heteroaryl, -NR 8a R 8b , -OR 8a , -SR 8a , -C (O) R 8a , -CO 2 R 8a , -C (O) NR 8a R 8b , -NR 8a COR
  • R 8a and R 8b are each independently selected from hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 alkenyl, -C 2-8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3-to 8-membered heterocyclyl or phenyl, each of said methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 alkenyl, -C 2-8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3-to 8-
  • R 8e and R 8f are each independently selected from hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 alkenyl, -C 2-8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3-to 8-membered heterocyclyl, phenyl or 5-to 12-membered heteroaryl;
  • R 8 , R 9 and R 10 are each independently selected from hydrogen, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3-to 8-membered heterocyclyl, -NR 8a R 8b , -OR 8a , -SR 8a , -C (O) R 8a , -CO 2 R 8a , -C (O) NR 8a R 8b , -NR 8a COR 8b , -NR 8a CO 2 R 8b or -NR 8a SO 2 R 8b or -CN; each of methyl, ethyl, propyl, butyl, pentyl,
  • R 8a and R 8b are each independently selected from hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 alkenyl, -C 2-8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3-to 8-membered heterocyclyl or phenyl;
  • R 8e and R 8f are each independently selected from hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3-to 8-membered heterocyclyl, phenyl or 5-to 12-membered heteroaryl;
  • R 8 , R 9 and R 10 are each independently selected from hydrogen, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 3-to 8-membered heterocyclyl, -NR 8a R 8b , -OR 8a , -CO 2 R 8a or -C (O) NR 8a R 8b ; each of methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or 3-to 8-membered heterocyclyl is optionally substituted with at least one R 8c ;
  • R 8a and R 8b are each independently selected from hydrogen, methyl, ethyl, propyl, butyl, pentyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 3-membered heterocyclyl, 4-membered heterocyclyl, 5-membered heterocyclyl or 6-membered heterocyclyl;
  • R 8e and R 8f are each independently selected from hydrogen, methyl, ethyl, propyl, cyclopropyl, cyclobutyl, cyclopentyl;
  • R 8 , R 9 and R 10 are each independently selected from H, F, Cl, Br, methyl, ethyl, propyl (n-propyl or iso-propyl) , butyl (n-butyl, sec-butyl, iso-butyl or tert- butyl) , cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, -COOH, -CONH 2 , -CH 2 OCH 3 or -CH 2 OH.
  • Aspect 9 The synthetic method of any one of the preceding Aspects, wherein the is selected from
  • Aspect 10 The synthetic method of any one of the preceding Aspects, wherein the reaction reagents of step A comprise condensation agent;
  • the reaction reagents of step A comprise 2- (7-Azabenzotriazol-1-yl) -N, N, N', N'-tetramethyluronium hexafluorophosphate (HATU) , O (7Azabenzotriazol1yl) N, N, N', N'-tetramethyluronium hexafluophosphate (HBTU) , Dicyclohexylcarbodiimide (DCC) , 1- (3-Dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (EDC) , or any combinations of the said non nucleophilic bases;
  • reaction reagents of step A comprise 2- (7-Azabenzotriazol-1-yl) -N, N, N', N'-tetramethyluronium hexafluorophosphate (HATU) , O (7Azabenzotriazol1yl) N, N, N', N'-tetramethyluronium hexafluophosphate (HBTU) , or any combinations of the said non nucleophilic bases;
  • reaction reagents of step A comprise 2- (7-Azabenzotriazol-1-yl) -N, N, N', N'-tetramethyluronium hexafluorophosphate (HATU) ;
  • reaction reagents of step A further comprise organic base selected from DIEA.
  • Aspect 11 The synthetic method of any one of the preceding Aspects, wherein the reaction temperature of Step A is -40 °C to 40 °C; perferably, the reaction temperature of Step A is -20 °C to 30 °C; more perferably, the reaction temperature of Step A is 0 °C to 25 °C; even more perferably, the reaction temperature of Step A is 20 °C to 25 °C; even more perferably, the reaction temperature of Step A is room temperature;
  • reaction time of Step A is 1-60 minutes; preferably, the reaction time of Step A is 10-50 minutes; more preferably, the reaction time of Step A is 20-40 minutes; even more preferably, the reaction time of Step A is 30 minutes.
  • Aspect 13 The synthetic method of any one of the preceding Aspects, wherein the method further comprises:
  • reaction reagents of step B comprise base, preferably, the reaction reagents of step B comprise NaOH, KOH, LiOH, MeONa or EtONa, or any combinations of the said bases;
  • reaction reagents of step B comprise NaOH or LiOH.
  • Aspect 14 The synthetic method of any one of the preceding Aspects, wherein the reaction temperature of Step B is -40 °C to 60 °C; perferably, the reaction temperature of Step B is -20 °C to 40 °C; more perferably, the reaction temperature of Step B is 0 °C to 30 °C; even more perferably, the reaction temperature of Step B is 20 °C to 25 °C; even more perferably, the reaction temperature of Step B is room temperature;
  • Aspect 15 The synthetic method of any one of the preceding Aspects, wherein the reaction time of Step B is 1-10 hours; preferably, the reaction time of Step B is 1-8 hours; more preferably, the reaction time of Step B is 1.5-5 hours; even more preferably, the reaction time of Step B is 2 hours.
  • Aspect 16 The synthetic method of any one of the preceding Aspects, wherein the method further comprises:
  • reaction reagents of step C comprise counterattack reagent, preferably, the reaction reagents of step C comprise BrCN.
  • Aspect 17 The synthetic method of any one of the preceding Aspects, wherein the reaction temperature of Step C is -40 °C to 60 °C; perferably, the reaction temperature of Step C is -20 °C to 40 °C; more perferably, the reaction temperature of Step C is 0 °C to 30 °C; even more perferably, the reaction temperature of Step C is 20 °C to 25 °C; even more perferably, the reaction temperature of Step C is room temperature;
  • Aspect 18 The synthetic method of any one of the preceding Aspects, wherein the reaction time of Step C is 1-10 hours; preferably, the reaction time of Step C is 2-8 hours; more preferably, the reaction time of Step C is 3-5 hours; even more preferably, the reaction time of Step C is 4 hours.
  • alkyl includes a hydrocarbon group selected from linear and branched, saturated hydrocarbon groups comprising from 1 to 18, such as from 1 to 12, further such as from 1 to 10, more further such as from 1 to 8, or from 1 to 6, or from 1 to 4, carbon atoms.
  • alkyl groups comprising from 1 to 6 carbon atoms include, but not limited to, methyl, ethyl, 1-propyl or n-propyl ( “n-Pr” ) , 2-propyl or isopropyl ( “i-Pr” ) , 1-butyl or n-butyl ( “n-Bu” ) , 2-methyl-1-propyl or isobutyl ( “i-Bu” ) , 1-methylpropyl or s-butyl ( “s-Bu” ) , 1, 1-dimethylethyl or t-butyl ( “t-Bu” ) , 1-pentyl, 2-pentyl, 3-pentyl, 2-methyl-2-butyl, 3-methyl-2-butyl, 3-methyl-1-butyl, 2-methyl-1-butyl, 1-hexyl, 2-hexyl, 3-hexyl, 2-methyl-2-penty
  • propyl includes 1-propyl or n-propyl ( “n-Pr” ) , 2-propyl or isopropyl ( “i-Pr” ) .
  • butyl includes 1-butyl or n-butyl ( “n-Bu” ) , 2-methyl-1-propyl or isobutyl ( “i-Bu” ) , 1-methylpropyl or s-butyl ( “s-Bu” ) , 1, 1-dimethylethyl or t-butyl ( “t-Bu” ) .
  • pentyl includes 1-pentyl, 2-pentyl, 3-pentyl, 2-methyl-2-butyl, 3-methyl-2-butyl, 3-methyl-1-butyl, 2-methyl-1-butyl.
  • hexyl includes 1-hexyl, 2-hexyl, 3-hexyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 3-methyl-3-pentyl, 2-methyl-3-pentyl, 2, 3-dimethyl-2-butyl and 3, 3-dimethyl-2-butyl.
  • alkylene refers to a divalent alkyl group by removing two hydrogen from alkane.
  • Alkylene includes but not limited to methylene, ethylene, propylene, and so on.
  • halogen includes fluoro (F) , chloro (Cl) , bromo (Br) and iodo (I) .
  • alkenyl group e.g., C 2-6 alkenyl
  • examples of the alkenyl group, e.g., C 2-6 alkenyl include, but not limited to ethenyl or vinyl, prop-1-enyl, prop-2-enyl, 2-methylprop-1-enyl, but-1-enyl, but-2-enyl, but-3-enyl, buta-1, 3-dienyl, 2-methylbuta-1, 3-dienyl, hex-1-enyl, hex-2-enyl, hex-3-enyl, hex-4-enyl, and hexa-1, 3-dienyl groups.
  • alkenylene refers to a divalent alkenyl group by removing two hydrogen from alkene.
  • Alkenylene includes but not limited to, vinylidene, butenylene, and so on.
  • alkynyl includes a hydrocarbon group selected from linear and branched hydrocarbon group, comprising at least one C ⁇ C triple bond and from 2 to 18, such as 2 to 8, further such as from 2 to 6, carbon atoms.
  • alkynyl group e.g., C 2-6 alkynyl
  • alkynylene refers to a divalent alkynyl group by removing two hydrogen from alkyne.
  • Alkynylene includes but not limited to ethynylene and so on.
  • cycloalkyl includes a hydrocarbon group selected from saturated cyclic hydrocarbon groups, comprising monocyclic and polycyclic (e.g., bicyclic and tricyclic) groups including fused, bridged or spiro cycloalkyl.
  • the cycloalkyl group may comprise from 3 to 12, such as from 3 to 10, further such as 3 to 8, further such as 3 to 6, 3 to 5, or 3 to 4 carbon atoms.
  • the cycloalkyl group may be selected from monocyclic group comprising from 3 to 12, such as from 3 to 10, further such as 3 to 8, 3 to 6 carbon atoms.
  • Examples of the monocyclic cycloalkyl group include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, and cyclododecyl groups.
  • examples of the saturated monocyclic cycloalkyl group include, but not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl groups.
  • the cycloalkyl is a monocyclic ring comprising 3 to 6 carbon atoms (abbreviated as C 3-6 cycloalkyl) , including but not limited to, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
  • bicyclic cycloalkyl groups include those having from 7 to 12 ring atoms arranged as a fused bicyclic ring selected from [4, 4] , [4, 5] , [5, 5] , [5, 6] and [6, 6] ring systems, or as a bridged bicyclic ring selected from bicyclo [2.2.1] heptane, bicyclo [2.2.2] octane, and bicyclo [3.2.2] nonane.
  • bicyclic cycloalkyl groups include those arranged as a bicyclic ring selected from [5, 6] and [6, 6] ring systems.
  • spiro cycloalkyl includes a cyclic structure which contains carbon atoms and is formed by at least two rings sharing one atom.
  • fused cycloalkyl includes a bicyclic cycloalkyl group as defined herein which is saturated and is formed by two or more rings sharing two adjacent atoms.
  • bridged cycloalkyl includes a cyclic structure which contains carbon atoms and is formed by two rings sharing two atoms which are not adjacent to each other.
  • 7 to 10 membered bridged cycloalkyl includes a cyclic structure which contains 7 to 12 carbon atoms and is formed by two rings sharing two atoms which are not adjacent to each other.
  • fused cycloalkyl, fused cycloalkenyl, or fused cycloalkynyl include but are not limited to bicyclo [1.1.0] butyl, bicyclo [2.1.0] pentyl, bicyclo [3.1.0] hexyl, bicyclo [4.1.0] heptyl, bicyclo [3.3.0] octyl, bicyclo [4.2.0] octyl, decalin, as well as benzo 3 to 8 membered cycloalkyl, benzo C 4-6 cycloalkenyl, 2, 3-dihydro-1H-indenyl, 1H-indenyl, 1, 2, 3, 4-tetralyl, 1, 4-dihydronaphthyl, etc.
  • Preferred embodiments are 8 to 9 membered fused rings, which refer to cyclic structures containing 8 to 9 ring atoms within the above examples.
  • aryl used alone or in combination with other terms includes a group selected from:
  • bicyclic ring systems such as 7 to 12 membered bicyclic ring systems, wherein at least one ring is carbocyclic and aromatic, e.g., naphthyl and indanyl; and,
  • tricyclic ring systems such as 10 to 15 membered tricyclic ring systems wherein at least one ring is carbocyclic and aromatic, e.g., fluorenyl.
  • a monocyclic or bicyclic aromatic hydrocarbon ring has 5 to 10 ring-forming carbon atoms (i.e., C 5-10 aryl) .
  • Examples of a monocyclic or bicyclic aromatic hydrocarbon ring include, but not limited to, phenyl, naphth-1-yl, naphth-2-yl, anthracenyl, phenanthrenyl, and the like.
  • the aromatic hydrocarbon ring is a naphthalene ring (naphth-1-yl or naphth-2-yl) or phenyl ring.
  • the aromatic hydrocarbon ring is a phenyl ring.
  • bicyclic fused aryl includes a bicyclic aryl ring as defined herein.
  • the typical bicyclic fused aryl is naphthalene.
  • heteroaryl includes a group selected from:
  • 5-, 6-or 7-membered aromatic, monocyclic rings comprising at least one heteroatom, for example, from 1 to 4, or, in some embodiments, from 1 to 3, in some embodiments, from 1 to 2, heteroatoms, selected from nitrogen (N) , sulfur (S) and oxygen (O) , with the remaining ring atoms being carbon;
  • 7-to 12-membered bicyclic rings comprising at least one heteroatom, for example, from 1 to 4, or, in some embodiments, from 1 to 3, or, in other embodiments, 1 or 2, heteroatoms, selected from N, O, and S, with the remaining ring atoms being carbon and wherein at least one ring is aromatic and at least one heteroatom is present in the aromatic ring; and
  • 11-to 14-membered tricyclic rings comprising at least one heteroatom, for example, from 1 to 4, or in some embodiments, from 1 to 3, or, in other embodiments, 1 or 2, heteroatoms, selected from N, O, and S, with the remaining ring atoms being carbon and wherein at least one ring is aromatic and at least one heteroatom is present in an aromatic ring.
  • the total number of S and O atoms in the heteroaryl group exceeds 1, those heteroatoms are not adjacent to one another. In some embodiments, the total number of S and O atoms in the heteroaryl group is not more than 2. In some embodiments, the total number of S and O atoms in the aromatic heterocycle is not more than 1.
  • the heteroaryl group contains more than one heteroatom ring member, the heteroatoms may be the same or different. The nitrogen atoms in the ring (s) of the heteroaryl group can be oxidized to form N-oxides.
  • bicyclic fused heteroaryl includes a 7-to 12-membered, preferably 7-to 10-membered, more preferably 9-or 10-membered fused bicyclic heteroaryl ring as defined herein.
  • a bicyclic fused heteroaryl is 5-membered/5-membered, 5-membered/6-membered, 6-membered/6-membered, or 6-membered/7-membered bicyclic. The group can be attached to the remainder of the molecule through either ring.
  • Heterocyclyl , “heterocycle” or “heterocyclic” are interchangeable and include a non-aromatic heterocyclyl group comprising one or more heteroatoms selected from nitrogen, oxygen or optionally oxidized sulfur as ring members, with the remaining ring members being carbon, including monocyclic, fused, bridged, and spiro ring, i.e., containing monocyclic heterocyclyl, bridged heterocyclyl, spiro heterocyclyl, and fused heterocyclic groups.
  • H or “hydrogen” disclosed herein includes Hydrogen and the non-radioisotope deuterium.
  • At least one substituent includes, for example, from 1 to 4, such as from 1 to 3, further as 1 or 2, substituents, provided that the theory of valence is met.
  • at least one substituent F disclosed herein includes from 1 to 4, such as from 1 to 3, further as 1 or 2, substituents F.
  • divalent refers to a linking group capable of forming covalent bonds with two other moieties.
  • a divalent cycloalkyl group refers to a cycloalkyl group obtained by removing two hydrogen from the corresponding cycloalkane to form a linking group.
  • divalent aryl group refers to a cycloalkyl group obtained by removing two hydrogen from the corresponding cycloalkane to form a linking group.
  • divalent heterocyclyl group or “divalent heteroaryl group” should be understood in a similar manner.
  • Enantiomers refer to two stereoisomers of a compound which are non-superimposable mirror images of one another. Where the compounds disclosed herein possess two or more asymmetric centers, they may additionally exist as diastereomers. Enantiomers and diastereomers fall within the broader class of stereoisomers. All such possible stereoisomers as substantially pure resolved enantiomers, racemic mixtures thereof, as well as mixtures of diastereomers are intended to be included. All stereoisomers of the compounds disclosed herein and/or pharmaceutically acceptable salts thereof are intended to be included. Unless specifically mentioned otherwise, reference to one isomer applies to any of the possible isomers. Whenever the isomeric composition is unspecified, all possible isomers are included.
  • substituents found on such ring system may adopt cis and trans formations.
  • Cis formation means that both substituents are found on the upper side of the 2 substituent placements on the carbon, while trans would mean that they were on opposing sides.
  • the di-substituted cyclic ring system may be cyclohexyl or cyclobutyl ring.
  • reaction products from one another and/or from starting materials.
  • the desired products of each step or series of steps is separated and/or purified (hereinafter separated) to the desired degree of homogeneity by the techniques common in the art.
  • separations involve multiphase extraction, crystallization from a solvent or solvent mixture, distillation, sublimation, or chromatography.
  • Chromatography can involve any number of methods including, for example: reverse-phase and normal phase; size exclusion; ion exchange; high, medium and low pressure liquid chromatography methods and apparatus; small scale analytical; simulated moving bed ( "SMB” ) and preparative thin or thick layer chromatography, as well as techniques of small scale thin layer and flash chromatography.
  • SMB simulated moving bed
  • Diastereomers refer to stereoisomers of a compound with two or more chiral centers but which are not mirror images of one another. Diastereomeric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods well known to those skilled in the art, such as by chromatography and/or fractional crystallization.
  • Enantiomers can be separated by converting the enantiomeric mixture into a diastereomeric mixture by reaction with an appropriate optically active compound (e.g., chiral auxiliary such as a chiral alcohol or Mosher’s acid chloride) , separating the diastereomers and converting (e.g., hydrolyzing) the individual diastereoisomers to the corresponding pure enantiomers.
  • an appropriate optically active compound e.g., chiral auxiliary such as a chiral alcohol or Mosher’s acid chloride
  • Enantiomers can also be separated by use of a chiral HPLC column.
  • a single stereoisomer e.g., a substantially pure enantiomer
  • Racemic mixtures of chiral compounds of the invention can be separated and isolated by any suitable method, including: (1) formation of ionic, diastereomeric salts with chiral compounds and separation by fractional crystallization or other methods, (2) formation of diastereomeric compounds with chiral derivatizing reagents, separation of the diastereomers, and conversion to the pure stereoisomers, and (3) separation of the substantially pure or enriched stereoisomers directly under chiral conditions. See: Wainer, Irving W., Ed. Drug Stereochemistry: Analytical Methods and Pharmacology. New York: Marcel Dekker, Inc., 1993.
  • tautomers Some of the compounds disclosed herein may exist with different points of attachment of hydrogen, referred to as tautomers.
  • keto and enol forms individually as well as mixtures thereof, are also intended to be included where applicable.
  • compounds including pyrazolyl may under go tautomerism to form a different ring like below:
  • compounds including guanidinyl in the ring may under go tautomerism to form a different ring like below:
  • Prodrug refers to a derivative of an active agent that requires a transformation within the body to release the active agent. In some embodiments, the transformation is an enzymatic transformation. Prodrugs are frequently, although not necessarily, pharmacologically inactive until converted to the active agent.
  • deuterated analog refers to a derivative of an active agent that an arbitrary hydrogen is substituted with deuterium.
  • the deuterated site is on the Warhead moiety.
  • the deuterated site is on the Linker moiety.
  • the deuterated site is on the Degron moiety.
  • “Pharmaceutically acceptable salts” refer to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio.
  • a pharmaceutically acceptable salt may be prepared in situ during the final isolation and purification of the compounds disclosed herein, or separately by reacting the free base function with a suitable organic acid or by reacting the acidic group with a suitable base.
  • the term also includes salts of the stereoisomers (such as enantiomers and/or diastereomers) , tautomers and prodrugs of the compound of the invention.
  • the free base can be obtained by basifying a solution of the acid salt.
  • an addition salt such as a pharmaceutically acceptable addition salt, may be produced by dissolving the free base in a suitable organic solvent and treating the solution with an acid, in accordance with conventional procedures for preparing acid addition salts from base compounds.
  • administration when applied to an animal, human, experimental subject, cell, tissue, organ, or biological fluid, mean contact of an exogenous pharmaceutical, therapeutic, diagnostic agent, or composition to the animal, human, subject, cell, tissue, organ, or biological fluid.
  • Treatment of a cell encompasses contact of a reagent to the cell, as well as contact of a reagent to a fluid, where the fluid is in contact with the cell.
  • administration and “treatment” also means in vitro and ex vivo treatments, e.g., of a cell, by a reagent, diagnostic, binding compound, or by another cell.
  • subject herein includes any organism, preferably an animal, more preferably a mammal (e.g., rat, mouse, dog, cat, and rabbit) and most preferably a human.
  • treated also generally refers to the acquisition of the desired pharmacological and/or physiological effect.
  • the effect may be prophylactic according to the prevention of the disease or its symptoms in whole or in part; and/or may be therapeutic according to the partial or complete stabilization or cure of the disease and/or the side effect due to the disease.
  • treated encompasses any treatment for the disease of a patient, including: (a) prevention of the disease or condition in the patient that may be predisposed to the disease or condition but has not yet been diagnosed; (b) inhibition of the symptoms of the disease, i.e., preventing its development; or (c) remission of the symptoms of the disease, i.e., causing regression of the disease or symptoms in whole or in part.
  • an effective amount refers to an amount of the active ingredient, such as compound that, when administered to a subject for treating a disease, or at least one of the clinical symptoms of a disease or disorder, is sufficient to affect such treatment for the disease, disorder, or symptom.
  • therapeutically effective amount can vary with the compound, the disease, disorder, and/or symptoms of the disease or disorder, severity of the disease, disorder, and/or symptoms of the disease or disorder, the age of the subject to be treated, and/or the weight of the subject to be treated. An appropriate amount in any given instance can be apparent to those skilled in the art or can be determined by routine experiments.
  • “therapeutically effective amount” is an amount of at least one compound and/or at least one stereoisomer, tautomer or prodrug thereof, and/or at least one pharmaceutically acceptable salt thereof disclosed herein effective to “treat” as defined herein, a disease or disorder in a subject.
  • the term “therapeutically effective amount” refers to the total amount of the combination objects for the effective treatment of a disease, a disorder or a condition.
  • disease refers to any disease, discomfort, illness, symptoms or indications, and can be interchangeable with the term “disorder” or “condition” .
  • C n-m or “C n -C m ” indicates a range which includes the endpoints, wherein n and m are integers and indicate the number of carbons. Examples include C 1-8 , C 1-6 , C 1 -C 8 , C 1 -C 6 and the like.
  • the percentages, proportions, ratios or parts used in the present application are by weight or volume.
  • the amount used in the present application is a weight or volume amount. It can be determined easily by those skilled in the art.
  • reaction flasks were fitted with rubber septa for the introduction of substrates and reagents via syringe; and glassware was oven dried and/or heat dried.
  • LCMS-1 LC-MS spectrometer (Agilent 1260 Infinity) Detector: MWD (190-400 nm) , Mass detector: 6120 SQ Mobile phase: A: water with 0.1%Formic acid, B: acetonitrile with 0.1%Formic acid Column: Poroshell 120 EC-C18, 4.6x50 mm, 2.7pm Gradient method: Flow: 1.8 mL/min Time (min) A (%) B (%)
  • LCMS, LCMS-3 LC-MS spectrometer (Agilent 1260 Infinity II) Detector: MWD (190-400 nm) , Mass detector: G6125C SQ Mobile phase: A: water with 0.1%Formic acid, B: acetonitrile with 0.1%Formic acid Column: Poroshell 120 EC-C18, 4.6x50 mm, 2.7pm Gradient method: Flow: 1.8 mL/min Time (min) A (%) B (%)
  • LCMS-2 LC-MS spectrometer (Agilent 1290 Infinity II) Detector: MWD (190-400 nm) , Mass detector: G6125C SQ Mobile phase: A: water with 0.1%Formic acid, B: acetonitrile with 0.1%Formic acid Column: Poroshell 120 EC-C18, 4.6x50 mm, 2.7pm Gradient method: Flow: 1.2 mL/min Time (min) A (%) B (%)
  • Preparative HPLC was conducted on a column (150 x 21.2 mm ID, 5 pm, Gemini NXC 18) at a flow rate of 20 ml/min, injection volume 2 ml, at room temperature and UV Detection at 214 nm and 254 nm.
  • Example 1 (7 1 s, 7 3 s, E) -5 6 -bromo-1 1 , 2 6 -dimethyl-5 2 , 5 3 -dihydro-1 1 H, 5 1 H-9-oxa-4-aza-5 (2, 1) -benzo [d] imidazola-2 (2, 4) -pyridina-1 (4, 5) -pyrazola-7 (1, 3) -cyclobutanacyclononaphan-3-one
  • Step 1 methyl (1s, 3s) -3-formylcyclobutane-1-carboxylate
  • Step 2 methyl (1s, 3s) -3- ( ( (tert-butylsulfinyl) amino) methyl) cyclobutane-1-carboxylate
  • Step 3 methyl (1s, 3s) -3- (aminomethyl) cyclobutane-1-carboxylate hydrochloride
  • Step 4 methyl (1s, 3s) -3- ( ( (5-bromo-2-nitrophenyl) amino) methyl) cyclobutane-1- carboxylate
  • Step 5 ( (1s, 3s) -3- ( ( (5-bromo-2-nitrophenyl) amino) methyl) cyclobutyl) methanol
  • Step 6 methyl 2- (5- ( ( (1s, 3s) -3- ( ( (5-bromo-2- nitrophenyl) amino) methyl) cyclobutyl) methoxy) -1-methyl-1H-pyrazol-4-yl) -6- methylisonicotinate
  • Step 7 methyl 2- (5- ( ( (1s, 3s) -3- ( ( (2-amino-5- bromophenyl) amino) methyl) cyclobutyl) methoxy) -1-methyl-1H-pyrazol-4-yl) -6- methylisonicotinate
  • Step 8 methyl 2- (5- ( ( (1s, 3s) -3- ( (6-bromo-2-imino-2, 3-dihydro-1H-benzo [d] imidazol-1- yl) methyl) cyclobutyl) methoxy) -1-methyl-1H-pyrazol-4-yl) -6-methylisonicotinate
  • Step 9 (7 1 s, 7 3 s, E) -5 6 -bromo-1 1 , 2 6 -dimethyl-5 2 , 5 3 -dihydro-1 1 H, 5 1 H-9-oxa-4-aza-5 (2, 1) - benzo [d] imidazola-2 (2, 4) -pyridina-1 (4, 5) -pyrazola-7 (1, 3) -cyclobutanacyclononaphan-3-one
  • Example 2 (7 1 r, 7 3 r, E) -5 6 -bromo-1 1 , 2 6 -dimethyl-5 2 , 5 3 -dihydro-1 1 H, 5 1 H-9-oxa-4-aza-5 (2, 1) -benzo [d] imidazola-2 (2, 4) -pyridina-1 (4, 5) -pyrazola-7 (1, 3) -cyclobutanacyclononaphan-3-one
  • Example 3 (7 1 s, 7 3 s, E) -1 1 , 2 6 -dimethyl-5 6 - (piperazin-1-ylmethyl) -5 2 , 5 3 -dihydro-1 1 H, 5 1 H-9-oxa-4-aza-5 (2, 1) -benzo [d] imidazola-2 (2, 4) -pyridina-1 (4, 5) -pyrazola-7 (1, 3) -cyclobutanacyclononaphan-3-one
  • Step 2 Tert-butyl 4- (3- ( ( ( (1s, 3s) -3- (methoxycarbonyl) cyclobutyl) methyl) amino) -4- nitrobenzyl) piperazine-1-carboxylate
  • Step 3 Tert-butyl 4- (3- ( ( ( (1s, 3s) -3- (hydroxymethyl) cyclobutyl) methyl) amino) -4- nitrobenzyl) piperazine-1-carboxylate
  • Step 4 Tert-butyl 4- (3- ( ( ( (1s, 3s) -3- ( ( (4- (4- (methoxycarbonyl) -6-methylpyridin-2-yl) -1- methyl-1H-pyrazol-5-yl) oxy) methyl) cyclobutyl) methyl) amino) -4-nitrobenzyl) piperazine-1- carboxylate
  • Step 5 Tert-butyl 4- (4-amino-3- ( ( ( (1s, 3s) -3- ( ( (4- (4- (methoxycarbonyl) -6-methylpyridin-2- yl) -1-methyl-1H-pyrazol-5-yl) oxy) methyl) cyclobutyl) methyl) amino) benzyl) piperazine-1- carboxylate
  • Step 6 Tert-butyl 4- ( (2-imino-3- ( ( (1s, 3s) -3- ( ( (4- (4- (methoxycarbonyl) -6-methylpyridin-2-yl) - 1-methyl-1H-pyrazol-5-yl) oxy) methyl) cyclobutyl) methyl) -2, 3-dihydro-1H-benzo [d] imidazol-5- yl) methyl) piperazine-1-carboxylate
  • Step 7 2- (5- ( ( (1s, 3s) -3- ( (6- ( (4- (tert-butoxycarbonyl) piperazin-1-yl) methyl) -2-imino-2, 3- dihydro-1H-benzo [d] imidazol-1-yl) methyl) cyclobutyl) methoxy) -1-methyl-1H-pyrazol-4-yl) -6- methylisonicotinic acid
  • reaction mixture was adjusted to 5-6 with 1N HCl solution, and then extracted with DCM (20 mL x 3) .
  • the combined organic phase was washed with brine (30 mL) , dried over Na 2 SO 4 , filtered and concentrated in vacuum to afford 2- (5- ( ( (1s, 3s) -3- ( (6- ( (4- (tert-butoxycarbonyl) piperazin-1-yl) methyl) -2-imino-2, 3-dihydro-1H-benzo [d] imidazol-1-yl) methyl) cyclobutyl) methoxy) -1-methyl-1H-pyrazol-4-yl) -6-methylisonicotinic acid (450 mg, 94.3%) .
  • [M+H] + 645.6.
  • Step 8 Tert-butyl 4- ( ( (7 1 s, 7 3 s, E) -1 1 , 2 6 -dimethyl-3-oxo-5 2 , 5 3 -dihydro-1 1 H, 5 1 H-9-oxa-4-aza- 5 (2, 1) -benzo [d] imidazola-2 (2, 4) -pyridina-1 (4, 5) -pyrazola-7 (1, 3) -cyclobutanacyclononaphane-5 6 - yl) methyl) piperazine-1-carboxylate
  • Step 9 (7 1 s, 7 3 s, E) -1 1 , 2 6 -dimethyl-5 6 - (piperazin-1-ylmethyl) -5 2 , 5 3 -dihydro-1 1 H, 5 1 H-9-oxa-4- aza-5 (2, 1) -benzo [d] imidazola-2 (2, 4) -pyridina-1 (4, 5) -pyrazola-7 (1, 3) -cyclobutanacyclononaphan- 3-one
  • Example 4 (7 1 s, 7 3 s, E) -1 1 , 2 6 -dimethyl-5 6 - (piperazin-1-yl) -5 2 , 5 3 -dihydro-1 1 H, 5 1 H-9-oxa-4-aza-5 (2, 1) -benzo [d] imidazola-2 (2, 4) -pyridina-1 (4, 5) -pyrazola-7 (1, 3) -cyclobutanacyclononaphan-3-one
  • Step 1 tert-butyl 4- ( (7 1 s, 7 3 s, E) -1 1 , 2 6 -dimethyl-3-oxo-5 2 , 5 3 -dihydro-1 1 H, 5 1 H-9-oxa-4-aza- 5 (2, 1) -benzo [d] imidazola-2 (2, 4) -pyridina-1 (4, 5) -pyrazola-7 (1, 3) - cyclobutanacyclononaphane-5 6 -yl) piperazine-1-carboxylate
  • Example 1 (19.1g, 102 mmol) in DMA (500 mL) were added tert-butyl piperazine-1-carboxylate (22.8 g, 122 mmol) , t-BuONa (24.6 g, 256 mmol) , Ruphos (19.6 g, 20 mmol) and Pd 2 (dba) 3 (9.3 g, 10 mmol) at room temperature under nitrogen atmosphere.
  • the resulting mixture was stirred for 2 h at 100 °C under nitrogen atmosphere.
  • the mixture was allowed to cool down to room temperature.
  • the resulting mixture was concentrated under reduced pressure.
  • Step 2 (7 1 s, 7 3 s, E) -1 1 , 2 6 -dimethyl-5 6 - (piperazin-1-yl) -5 2 , 5 3 -dihydro-1 1 H, 5 1 H-9-oxa-4- aza-5 (2, 1) -benzo [d] imidazola-2 (2, 4) -pyridina-1 (4, 5) -pyrazola-7 (1, 3) - cyclobutanacyclononaphan-3-one
  • Example 5 (7 1 s, 7 3 s, E) -1 1 , 2 6 -dimethyl-5 6 - (4-oxopiperidin-1-yl) -5 2 , 5 3 -dihydro-1 1 H, 5 1 H-9-oxa-4-aza-5 (2, 1) -benzo [d] imidazola-2 (2, 4) -pyridina-1 (4, 5) -pyrazola-7 (1, 3) -cyclobutanacyclononaphan-3-one
  • Step 1 (7 1 s, 7 3 s, E) -1 1 , 2 6 -dimethyl-5 6 - (1, 4-dioxa-8-azaspiro [4.5] decan-8-yl) -5 2 , 5 3 - dihydro-1 1 H, 5 1 H-9-oxa-4-aza-5 (2, 1) -benzo [d] imidazola-2 (2, 4) -pyridina-1 (4, 5) -pyrazola- 7 (1, 3) -cyclobutanacyclononaphan-3-one
  • Step 2 (7 1 s, 7 3 s, E) -1 1 , 2 6 -dimethyl-5 6 - (4-oxopiperidin-1-yl) -5 2 , 5 3 -dihydro-1 1 H, 5 1 H-9-oxa- 4-aza-5 (2, 1) -benzo [d] imidazola-2 (2, 4) -pyridina-1 (4, 5) -pyrazola-7 (1, 3) - cyclobutanacyclononaphan-3-one
  • Example 6 (7 1 s, 7 3 s, E) -1 1 , 2 6 -dimethyl-5 6 - (2-oxopiperazin-1-yl) -5 2 , 5 3 -dihydro-1 1 H, 5 1 H-9- oxa-4-aza-5 (2, 1) -benzo [d] imidazola-2 (2, 4) -pyridina-1 (4, 5) -pyrazola-7 (1, 3) -cyclobutanacyclononaphan-3-one
  • Step 1 tert-butyl 4- (3- ( ( ( (1s, 3s) -3- ( ( (4- (4- (methoxycarbonyl) -6-methylpyridin-2-yl) -1- methyl-1H-pyrazol-5-yl) oxy) methyl) cyclobutyl) methyl) amino) -4-nitrophenyl) -3-oxopiperazine-1- carboxylate
  • Step 2 tert-butyl 4- (4-amino-3- ( ( ( (1s, 3s) -3- ( ( (4- (4- (methoxycarbonyl) -6-methylpyridin-2-yl) - 1-methyl-1H-pyrazol-5-yl) oxy) methyl) cyclobutyl) methyl) amino) phenyl) -3-oxopiperazine-1- carboxylate
  • Step 3 tert-butyl 4- (2-amino-1- ( ( (1s, 3s) -3- ( ( (4- (4- (methoxycarbonyl) -6-methylpyridin-2-yl) - 1-methyl-1H-pyrazol-5-yl) oxy) methyl) cyclobutyl) methyl) -1H-benzo [d] imidazol-6-yl) -3- oxopiperazine-1-carboxylate
  • Step 4 2- (5- ( ( (1s, 3s) -3- ( (2-amino-6- (4- (tert-butoxycarbonyl) -2-oxopiperazin-1-yl) -1H- benzo [d] imidazol-1-yl) methyl) cyclobutyl) methoxy) -1-methyl-1H-pyrazol-4-yl) -6- methylisonicotinic acid
  • Step 5 tert-butyl 4- ( (7 1 s, 7 3 s, E) -1 1 , 2 6 -dimethyl-3-oxo-5 2 , 5 3 -dihydro-1 1 H, 5 1 H-9-oxa-4-aza- 5 (2, 1) -benzo [d] imidazola-2 (2, 4) -pyridina-1 (4, 5) -pyrazola-7 (1, 3) -cyclobutanacyclononaphane-5 6 - yl) -3-oxopiperazine-1-carboxylate
  • Step 6 (7 1 s, 7 3 s, E) -1 1 , 2 6 -dimethyl-5 6 - (2-oxopiperazin-1-yl) -5 2 , 5 3 -dihydro-1 1 H, 5 1 H-9-oxa-4- aza-5 (2, 1) -benzo [d] imidazola-2 (2, 4) -pyridina-1 (4, 5) -pyrazola-7 (1, 3) -cyclobutanacyclononaphan- 3-one
  • Example 7 (7 1 s, 7 3 R, E) -5 6 - ( (S) -3- (hydroxymethyl) piperazin-1-yl) -1 1 , 2 6 -dimethyl-5 2 , 5 3 -dihydro-1 1 H, 5 1 H-9-oxa-4-aza-5 (2, 1) -benzo [d] imidazola-2 (2, 4) -pyridina-1 (4, 5) -pyrazola-7 (1, 3) -cyclobutanacyclononaphan-3-one
  • Step 1 tert-butyl (S) -4- ( (7 1 s, 7 3 R, E) -1 1 , 2 6 -dimethyl-3-oxo-5 2 , 5 3 -dihydro-1 1 H, 5 1 H-9-oxa-4- aza-5 (2, 1) -benzo [d] imidazola-2 (2, 4) -pyridina-1 (4, 5) -pyrazola-7 (1, 3) - cyclobutanacyclononaphane-5 6 -yl) -2- (hydroxymethyl) piperazine-1-carboxylate
  • Example 1 A mixture of Example 1 (506 mg, 1 mmol) , tert-butyl (R) -2- (hydroxymethyl) piperazine-1-carboxylate (325 mg, 1.5 mmol) , Pd 2 dba 3 (91 mg, 0.1 mmol) , Ruphos (93 mg, 0.2 mmol) , and t-BuONa (288 mg, 3 mmol) in DMA (10 mL) was stirred in a round bottom flask at 90 °C for 2 hours under N 2 . Water (20 mL) was added, and the mixture was extracted with DCM (50 mL ⁇ 3) . The combined organic layer was dried over Na 2 SO 4 .
  • Step 2 (7 1 s, 7 3 R, E) -5 6 - ( (S) -3- (hydroxymethyl) piperazin-1-yl) -1 1 , 2 6 -dimethyl-5 2 , 5 3 -dihydro- 1 1 H, 5 1 H-9-oxa-4-aza-5 (2, 1) -benzo [d] imidazola-2 (2, 4) -pyridina-1 (4, 5) -pyrazola-7 (1, 3) - cyclobutanacyclononaphan-3-one
  • Example 8 (7 1 s, 7 3 R, E) -1 1 , 2 6 -dimethyl-5 6 - ( (S) -2-methylpiperazin-1-yl) -5 2 , 5 3 -dihydro-1 1 H, 5 1 H-9-oxa-4-aza-5 (2, 1) -benzo [d] imidazola-2 (2, 4) -pyridina-1 (4, 5) -pyrazola-7 (1, 3) -cyclobutanacyclononaphan-3-one
  • Step 1 tert-butyl (S) -4- ( (7 1 s, 7 3 R, E) -1 1 , 2 6 -dimethyl-3-oxo-5 2 , 5 3 -dihydro-1 1 H, 5 1 H-9-oxa- 4-aza-5 (2, 1) -benzo [d] imidazola-2 (2, 4) -pyridina-1 (4, 5) -pyrazola-7 (1, 3) - cyclobutanacyclononaphane-5 6 -yl) -3-methylpiperazine-1-carboxylate
  • Example 1 To a stirred solution of Example 1 (300 mg, 0.59 mmol) and tert-butyl (S) -3-methylpiperazine-1-carboxylate (237 mg, 1.18 mmol) in DMA (15 mL) were added t-BuONa (227 mg, 2.37 mmol) , Ruphos (110 mg, 0.24 mmol) and Pd 2 (dba) 3 (108 mg, 0.12 mmol) at room temperature under nitrogen atmosphere. The resulting mixture was stirred for 2 h at 100 °C under nitrogen atmosphere. The mixture was allowed to cool down to room temperature. The resulting mixture was concentrated under reduced pressure.
  • Step 2 (7 1 s, 7 3 R, E) -1 1 , 2 6 -dimethyl-5 6 - ( (S) -2-methylpiperazin-1-yl) -5 2 , 5 3 -dihydro- 1 1 H, 5 1 H-9-oxa-4-aza-5 (2, 1) -benzo [d] imidazola-2 (2, 4) -pyridina-1 (4, 5) -pyrazola-7 (1, 3) - cyclobutanacyclononaphan-3-one
  • Step 2 Tert-butyl 4- (3- ( ( ( (1s, 3s) -3- (methoxycarbonyl) cyclobutyl) methyl) amino) -4- nitrobenzyl) piperazine-1-carboxylate
  • Step 3 Tert-butyl 4- (3- ( ( ( (1s, 3s) -3- (hydroxymethyl) cyclobutyl) methyl) amino) -4- nitrobenzyl) piperazine-1-carboxylate
  • Step 4 Tert-butyl 4- (3- ( ( ( (1s, 3s) -3- ( ( (4- (4- (methoxycarbonyl) -6-methylpyridin-2-yl) -1- methyl-1H-pyrazol-5-yl) oxy) methyl) cyclobutyl) methyl) amino) -4-nitrobenzyl) piperazine-1- carboxylate
  • Step 5 Tert-butyl 4- (4-amino-3- ( ( ( (1s, 3s) -3- ( ( (4- (4- (methoxycarbonyl) -6-methylpyridin- 2-yl) -1-methyl-1H-pyrazol-5-yl) oxy) methyl) cyclobutyl) methyl) amino) benzyl) piperazine-1- carboxylate
  • Step 6 Tert-butyl 4- ( (2-imino-3- ( ( (1s, 3s) -3- ( ( (4- (4- (methoxycarbonyl) -6-methylpyridin- 2-yl) -1-methyl-1H-pyrazol-5-yl) oxy) methyl) cyclobutyl) methyl) -2, 3-dihydro-1H- benzo [d] imidazol-5-yl) methyl) piperazine-1-carboxylate
  • Step 7 2- (5- ( ( (1s, 3s) -3- ( (6- ( (4- (tert-butoxycarbonyl) piperazin-1-yl) methyl) -2-imino-2, 3- dihydro-1H-benzo [d] imidazol-1-yl) methyl) cyclobutyl) methoxy) -1-methyl-1H-pyrazol-4-yl) - 6-methylisonicotinic acid
  • reaction mixture was adjusted to 5-6 with 1N HCl solution, and then extracted with DCM (20 mL x 3) .
  • the combined organic phase was washed with brine (30 mL) , dried over Na 2 SO 4 , filtered and concentrated in vacuum to afford 2- (5- ( ( (1s, 3s) -3- ( (6- ( (4- (tert-butoxycarbonyl) piperazin-1-yl) methyl) -2-imino-2, 3-dihydro-1H-benzo [d] imidazol-1-yl) methyl) cyclobutyl) methoxy) -1-methyl-1H-pyrazol-4-yl) -6-methylisonicotinic acid (450 mg, 94.3%) .
  • [M+H] + 645.6.
  • Step 8 Tert-butyl 4- ( ( (7 1 s, 7 3 s, E) -1 1 , 2 6 -dimethyl-3-oxo-5 2 , 5 3 -dihydro-1 1 H, 5 1 H-9-oxa-4- aza-5 (2, 1) -benzo [d] imidazola-2 (2, 4) -pyridina-1 (4, 5) -pyrazola-7 (1, 3) - cyclobutanacyclononaphane-5 6 -yl) methyl) piperazine-1-carboxylate
  • Step 9 (7 1 s, 7 3 s, E) -1 1 , 2 6 -dimethyl-5 6 - (piperazin-1-ylmethyl) -5 2 , 5 3 -dihydro-1 1 H, 5 1 H-9- oxa-4-aza-5 (2, 1) -benzo [d] imidazola-2 (2, 4) -pyridina-1 (4, 5) -pyrazola-7 (1, 3) - cyclobutanacyclononaphan-3-one
  • Step 10 2, 6-bis (benzyloxy) -3- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) pyridine
  • Step 12 2, 6-bis (benzyloxy) -3- (4-bromo-2, 6-difluorophenyl) pyridine
  • Step 13 methyl 1- (4- (2, 6-bis (benzyloxy) pyridin-3-yl) -3, 5-difluorophenyl) azetidine-3- carboxylate
  • Step 14 1- (4- (2, 6-bis (benzyloxy) pyridin-3-yl) -3, 5-difluorophenyl) azetidine-3-carboxylic acid
  • Step 15 (R) -1- (4- (2, 6-dioxopiperidin-3-yl) -3, 5-difluorophenyl) azetidine-3-carboxylic acid
  • Step 16 (R) -3- (4- (3- (4- ( ( (7 1 s, 7 3 s, E) -11, 26-dimethyl-3-oxo-5 2 , 5 3 -dihydro-1 1 H, 5 1 H-9-oxa- 4-aza-5 (2, 1) -benzo [d] imidazola-2 (2, 4) -pyridina-1 (4, 5) -pyrazola-7 (1, 3) - cyclobutanacyclononaphane-5 6 -yl) methyl) piperazine-1-carbonyl) azetidin-1-yl) -2, 6- difluorophenyl) piperidine-2, 6-dione
  • the reaction was stirred at rt for 1 hr.
  • the reaction was quenched by water (5 mL) and the resulting mixture was extracted by DCM (10 mL x 3) , the combined organic phase was washed with brine (10 mL x 3) , dried over Na 2 SO 4 , filtered and concentrated in vacuum.
  • Step 1 2- ( (4- (2, 6-bis (benzyloxy) pyridin-3-yl) -3, 5-difluorophenyl) amino) ethan-1-ol
  • Step 2 3- (2, 6-difluoro-4- ( (2-hydroxyethyl) amino) phenyl) piperidine-2, 6-dione
  • Step 3 2- ( (4- (2, 6-dioxopiperidin-3-yl) -3, 5-difluorophenyl) amino) ethyl methanesulfonate
  • Step 4 (R) -3- (4- ( (2- (4- ( (7 1 s, 7 3 s, E) -1 1 , 2 6 -dimethyl-3-oxo-5 2 , 5 3 -dihydro-1 1 H, 5 1 H-9-oxa-4- aza-5 (2, 1) -benzo [d] imidazola-2 (2, 4) -pyridina-1 (4, 5) -pyrazola-7 (1, 3) - cyclobutanacyclononaphane-5 6 -yl) piperazin-1-yl) ethyl) amino) -2, 6-difluorophenyl) piperidine- 2, 6-dione
  • Step 1 tert-butyl 4- (3- ( ( (benzyloxy) carbonyl) amino) cyclobutyl) piperazine-1-carboxylate
  • Step 3 tert-butyl 4- ( (1s, 3s) -3- ( (4- (2, 6-bis (benzyloxy) pyridin-3-yl) -3, 5- difluorophenyl) amino) cyclobutyl) piperazine-1-carboxylate
  • Step 4 tert-butyl 4- ( (1s, 3s) -3- ( (4- (2, 6-dioxopiperidin-3-yl) -3, 5- difluorophenyl) amino) cyclobutyl) piperazine-1-carboxylate
  • Step 5 3- (2, 6-difluoro-4- ( ( (1s, 3s) -3- (piperazin-1-yl) cyclobutyl) amino) phenyl) piperidine- 2, 6-dione
  • Step 6 (R) -3- (4- ( ( (1S, 3S) -3- (4- ( (7 1 s, 7 3 S, E) -1 1 , 2 6 -dimethyl-3-oxo-5 2 , 5 3 -dihydro-1 1 H, 5 1 H- 9-oxa-4-aza-5 (2, 1) -benzo [d] imidazola-2 (2, 4) -pyridina-1 (4, 5) -pyrazola-7 (1, 3) - cyclobutanacyclononaphane-5 6 -yl) piperazin-1-yl) cyclobutyl) amino) -2, 6- difluorophenyl) piperidine-2, 6-dione
  • the resulting mixture was stirred for 2 h at 100 °C under nitrogen atmosphere. The mixture was allowed to cool down to room temperature. The resulting mixture was concentrated under reduced pressure. The residue was diluted with DCM (40 mL) , washed with sat. aq. NH 4 Cl (2 x 30 mL) and brine (50 mL) . The organic layer was dried over anhydrous Na 2 SO 4 , filtered and concentrated under reduced pressure.
  • Step 1 benzyl 4- (4- (2, 6-bis (benzyloxy) pyridin-3-yl) -3, 5-difluorophenyl) piperazine-1- carboxylate
  • Step 2 (R) -3- (2, 6-difluoro-4- (piperazin-1-yl) phenyl) piperidine-2, 6-dione
  • the title compound could also be purified by chiral SFC (column: Chiral ND (2) 3.0*100mm, 3um; solvent A: CO 2 , solvent B: IPA (0.1%DEA) , gradient (B%) : 10%to 50%in 2.0 min, hold 1.0 min at 50%; flow 2mL/min, retention time 1.979 min) .
  • Step 3 (R) -3- (4- (4- (1- ( (7 1 s, 7 3 s, E) -1 1 , 2 6 -dimethyl-3-oxo-5 2 , 5 3 -dihydro-1 1 H, 5 1 H-9-oxa-4- aza-5 (2, 1) -benzo [d] imidazola-2 (2, 4) -pyridina-1 (4, 5) -pyrazola-7 (1, 3) - cyclobutanacyclononaphane-5 6 -yl) piperidin-4-yl) piperazin-1-yl) -2, 6- difluorophenyl) piperidine-2, 6-dione
  • Step 1 8- (4- (2, 6-bis (benzyloxy) pyridin-3-yl) -3, 5-difluorophenyl) -1, 4-dioxa-8- azaspiro [4.5] decane
  • Step 2 3- (2, 6-difluoro-4- (1, 4-dioxa-8-azaspiro [4.5] decan-8-yl) phenyl) piperidine-2, 6- dione
  • Step 3 (R) -3- (2, 6-difluoro-4- (1, 4-dioxa-8-azaspiro [4.5] decan-8-yl) phenyl) piperidine- 2, 6-dione
  • Step 4 (R) -3- (2, 6-difluoro-4- (4-oxopiperidin-1-yl) phenyl) piperidine-2, 6-dione
  • Step 5 (R) -3- (4- (4- ( (S) -4- ( (7 1 s, 7 3 R, E) -1 1 , 2 6 -dimethyl-3-oxo-5 2 , 5 3 -dihydro-1 1 H, 5 1 H-9- oxa-4-aza-5 (2, 1) -benzo [d] imidazola-2 (2, 4) -pyridina-1 (4, 5) -pyrazola-7 (1, 3) - cyclobutanacyclononaphane-5 6 -yl) -2- (hydroxymethyl) piperazin-1-yl) piperidin-1-yl) -2, 6- difluorophenyl) piperidine-2, 6-dione
  • step 1 tert-butyl 4- ( (2- ( ( (benzyloxy) carbonyl) amino) ethyl) amino) piperidine-1- carboxylate
  • Step 2 tert-butyl 4- (N- (2- ( ( (benzyloxy) carbonyl) amino) ethyl) -2- chloroacetamido) piperidine-1-carboxylate
  • Step 3 benzyl 4- (1- (tert-butoxycarbonyl) piperidin-4-yl) -3-oxopiperazine-1-carboxylate
  • Step 4 tert-butyl 4- (2-oxopiperazin-1-yl) piperidine-1-carboxylate
  • Step 5 tert-butyl 4- (4- (4- (2, 6-bis (benzyloxy) pyridin-3-yl) -3, 5-difluorophenyl) -2- oxopiperazin-1-yl) piperidine-1-carboxylate
  • Step 6 tert-butyl 4- (4- (4- (2, 6-dioxopiperidin-3-yl) -3, 5-difluorophenyl) -2-oxopiperazin- 1-yl) piperidine-1-carboxylate
  • Step 7 3- (2, 6-difluoro-4- (3-oxo-4- (piperidin-4-yl) piperazin-1-yl) phenyl) piperidine-2, 6- dione
  • Step 8 (R) -3- (4- (4- (1- ( (7 1 s, 7 3 s, E) -1 1 , 2 6 -dimethyl-3-oxo-5 2 , 5 3 -dihydro-1 1 H, 5 1 H-9-oxa-4- aza-5 (2, 1) -benzo [d] imidazola-2 (2, 4) -pyridina-1 (4, 5) -pyrazola-7 (1, 3) - cyclobutanacyclononaphane-5 6 -yl) piperidin-4-yl) -3-oxopiperazin-1-yl) -2, 6- difluorophenyl) piperidine-2, 6-dione
  • H1975-clone#28 (Del19/T790M/C797S, or abbr: DTC) , H1975-clone#23 (Del19/C797S, or abbr: DC) , H1975-clone#25 (L858R/T790M/C797S, or abbr: LTC) and H1975-clone#8 (L858R/C797S, or abbr: LC) .
  • EGFR-Del19/T790M/C797S, EGFR-Del19/C797S, EGFR-L858R/T790M/C797S and EGFR-L858R/C797S were stably expressed in H1975 cell lines by lentivirus-mediated over-expression, respectively.
  • the EGFR over-expressed cells then underwent knockout, in which the EGFR targeting sgRNA was designed to only target the endogenous EGFR copies and preserve the exogenous EGFR copies.
  • the edited H1975 cells were seeded in 96 well plates at the concentration of 1 cell/well, cultured for about 2 weeks to allow single clones formation.
  • H1975-clone#28, H1975-clone#23, H1975-clone#25 and H1975-clone#8 were finally confirmed as homozygous Del19/T790M/C797S EGFR, Del19/C797S EGFR, L858R/T790M/C797S EGFR and L858R/C797S EGFR clones, respectively.
  • H1975-clone#28 (Del19/T790M/C797S, or abbr: DTC) , H1975-clone#23 (Del19/C797S, or abbr: DC) , H1975-clone#25 (L858R/T790M/C797S, or abbr: LTC) and H1975-clone#8 (L858R/C797S, or abbr: LC) cells are seeded at 20000 cells/well , 30000 cells/well, 10000 cells/well or 5000 cells/well correspondingly in cell culture medium [RPMI1640 (Gibco, Cat#72400-047) , 10%heat-inactive FBS, 1%PS (Gibco, Cat#10378) ] in Corning 96 well plate (Cat#3599) .
  • cell culture medium [RPMI1640 (Gibco, Cat#72400-047) , 10%heat-inactive FBS,
  • H1975-#25, H1975-#28, H1975-#23 and H1975-#8 cells are treated with compounds diluted in 0.2%DMSO cell culture medium on day 2, incubate for 16h, 37 °C, 5%CO 2 .
  • the final concentration of compounds in all assay is start with 10 ⁇ M, 5-fold dilution, total 8 doses were included.
  • Total-EGFR cellular kit 64NG1PEH were used for evaluating EGFR degradation.
  • HTRF lysis buffer After 16h treatment, add HTRF lysis buffer to each well; seal the plate and incubate 1 hour at room temperature on a plate shaker; Once the cells are lysed, 16 ⁇ L of cell lysate are transferred to a PE 384-well HTRF detection plate; 4 ⁇ L of pre-mixed HTRF antibodies are added to each well; cover the plate with a plate sealer, spin 1000 rpm for 1 min, incubate overnight at room temperature; read on BMG PheraStar with HTRF protocol (337nm-665nm-620nm) .
  • High control Cell group with added DMSO and without compound, indicating microplate readings without EGFR degradation.
  • Imax (Dmax) is the maximum percentage of inhibition (degradation) .
  • the IC 50 (DC 50 ) value of a compound can be obtained by fitting the following equation
  • X and Y are known values, and IC 50 , Hillslope, Top and Bottom are the parameters obtained by fitting with software.
  • Y is the inhibition percentage (calculated from the equation)
  • X is the concentration of the compound
  • IC 50 is the concentration of the compound when the 50%inhibition is reached. The smaller the IC 50 value is, the stronger the inhibitory ability of the compound is. Vice versa, the higher the IC 50 value is, the weaker the ability the inhibitory ability of the compound is
  • Hillslope represents the slope of the fitted curve, generally around 1 *
  • Bottom represents the minimum value of the curve obtained by data fitting, which is generally 0% ⁇ 20%
  • Top represents the maximum value of the curve obtained by data fitting, which is generally 100% ⁇ 20%.
  • the experimental data were fitted by calculating and analyzing with Dotmatics data analysis software.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne de nouveaux composés bifonctionnels formés par conjugaison de fractions d'inhibiteur d'EGFR avec des fractions de ligand de ligase E3, qui fonctionnent pour recruter des protéines ciblées par ubiquitine ligase E3 pour la dégradation, et leurs procédés de préparation et leurs utilisations.
PCT/CN2023/130819 2022-11-10 2023-11-09 Intermédiaires et procédé de composés pour la dégradation de la kinase egfr WO2024099400A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2022131194 2022-11-10
CNPCT/CN2022/131194 2022-11-10

Publications (1)

Publication Number Publication Date
WO2024099400A1 true WO2024099400A1 (fr) 2024-05-16

Family

ID=91031953

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2023/130819 WO2024099400A1 (fr) 2022-11-10 2023-11-09 Intermédiaires et procédé de composés pour la dégradation de la kinase egfr

Country Status (1)

Country Link
WO (1) WO2024099400A1 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021121261A1 (fr) * 2019-12-16 2021-06-24 北京泰德制药股份有限公司 Composé pour inhiber et induire la dégradation de la kinase egfr
CN113527335A (zh) * 2020-04-15 2021-10-22 南京圣和药业股份有限公司 作为egfr抑制剂的大环类化合物及其应用
CN114007698A (zh) * 2019-06-24 2022-02-01 勃林格殷格翰国际有限公司 作为egfr抑制剂的新型大环化合物和衍生物
CN114163454A (zh) * 2020-09-11 2022-03-11 上海翰森生物医药科技有限公司 含吡啶多环类衍生物抑制剂、其制备方法和应用
CN114656482A (zh) * 2020-12-23 2022-06-24 南京圣和药业股份有限公司 作为egfr抑制剂的大环杂环类化合物及其应用
WO2023001069A1 (fr) * 2021-07-23 2023-01-26 南京明德新药研发有限公司 Composés amides macrocycliques et leur application

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114007698A (zh) * 2019-06-24 2022-02-01 勃林格殷格翰国际有限公司 作为egfr抑制剂的新型大环化合物和衍生物
WO2021121261A1 (fr) * 2019-12-16 2021-06-24 北京泰德制药股份有限公司 Composé pour inhiber et induire la dégradation de la kinase egfr
CN113527335A (zh) * 2020-04-15 2021-10-22 南京圣和药业股份有限公司 作为egfr抑制剂的大环类化合物及其应用
CN114163454A (zh) * 2020-09-11 2022-03-11 上海翰森生物医药科技有限公司 含吡啶多环类衍生物抑制剂、其制备方法和应用
CN114656482A (zh) * 2020-12-23 2022-06-24 南京圣和药业股份有限公司 作为egfr抑制剂的大环杂环类化合物及其应用
WO2023001069A1 (fr) * 2021-07-23 2023-01-26 南京明德新药研发有限公司 Composés amides macrocycliques et leur application

Similar Documents

Publication Publication Date Title
WO2022012623A1 (fr) Dégradation d'egfr par conjugaison d'inhibiteurs d'egfr avec un ligand de ligase e3 et procédés d'utilisation
JP6114765B2 (ja) ＴＲＫキナーゼ阻害剤としての置換ピラゾロ［１，５−ａ］ピリミジン化合物
WO2022068849A1 (fr) Composés bifonctionnels pour la dégradation de l'egfr et procédés d'utilisation associés
AU2017206195A1 (en) N-pyrrolidinyl, n'-pyrazolyl- urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
CN108137539B (zh) 取代的苯并咪唑、它们的制备和它们作为药物的用途
KR20150082314A (ko) 트라이아졸로피라진
WO2022012622A1 (fr) Dégradation d'egfr par conjugaison d'inhibiteurs d'egfr avec un ligand de ligase e3 et procédés d'utilisation
US20230002369A1 (en) Bcl-2 INHIBITORS
WO2014078372A1 (fr) Composés de n-pyrrolidinyle urée, thio-urée,guanidine et cyanoguanidine en tant qu'inhibiteurs de la kinase trka
WO2022171123A1 (fr) Agents de dégradation d'egfr et procédés d'utilisation
JP2010523530A (ja) タンパク質キナーゼ阻害剤として有益な［２，６］ナフチリジン
WO2022228556A1 (fr) Agents de dégradation d'egfr et méthodes d'utilisation associées
WO2021180103A1 (fr) Dégradation de la tyrosine kinase de bruton (btk) par conjugaison d'inhibiteurs de btk avec un ligand de ligase e3 et procédés d'utilisation
KR20170036095A (ko) Smac 모방체로서의 6-알키닐 피리딘 유도체
WO2022268052A1 (fr) Ligands de (r)-glutarimide crbn et procédés d'utilisation
WO2024099400A1 (fr) Intermédiaires et procédé de composés pour la dégradation de la kinase egfr
WO2024099402A1 (fr) Procédé et intermédiaires de composés pour la dégradation de la kinase egfr
WO2018167019A1 (fr) Composés à base de tosylacétate et dérivés de ceux-ci utilisés en tant qu'inhibiteurs de phgdh
CN116600808A (zh) 一类作为kras突变体g12c抑制剂的四氢萘啶类衍生物、其制备方法及其应用
WO2024099395A1 (fr) Composés utilisés dans la dégradation de la kinase egfr
WO2023138607A1 (fr) Dégradation d'egfr par conjugaison d'inhibiteurs d'egfr avec un ligand de ligase e3 et procédés d'utilisation
WO2022227032A1 (fr) Agents de dégradation d'egfr et procédés d'utilisation associés
WO2023098656A1 (fr) Composés pour la dégradation de la kinase egfr
WO2023208172A1 (fr) Composés de 7-(pyrimidin-4-yl) quinolin-4 (1h)-one substitués en tant qu'inhibiteurs de kinase cycline-dépendante
WO2024088323A1 (fr) Composés de 6-(pyrimidin-4-yl)quinoléine substituée utilisés en tant qu'inhibiteurs de kinase dépendante des cyclines